Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the company’s latest milestone - commencement of dosing for the first patient in the ...
CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...
Subcutaneous administration of the anti-PD-1 monoclonal antibody toripalimab achieves similar drug exposure as the intravenous formulation in advanced non-squamous non-small cell lung cancer (NSCLC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results